ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Drug-Loaded Red Blood Cell-Derived Carriers for Targeted Delivery to Accelerate Tissue Regeneration.Pharmaceutics · 2026Article
- Red Blood Cell-Encapsulated Nanoparticles for Long-Circulating, Improved Specificity Functional MRI.Chemical & biomedical imaging · 2026Article
- Porcine Erythrocyte-PRRSV Interactions: Implications for Targeted Nanodrug Delivery.Veterinary sciences · 2026Article
- Cell-based drug delivery for combating bacteria: focus on refractory infections.Journal of nanobiotechnology · 2026Review
- Current state of the treatment landscape of phenylketonuria.Orphanet journal of rare diseases · 2025Review
- Red blood cells could protect miRNAs from degradation or loss thanks to Argonaute 2 binding.FEBS open bio · 2025Article
- Red Blood Cell Membrane Vesicles for siRNA Delivery: A Biocompatible Carrier With Passive Tumor Targeting and Prolonged Plasma Residency.International journal of nanomedicine · 2025Article
- The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review.Cerebellum (London, England) · 2024Review
- Biochemical Studies on Human Ornithine Aminotransferase Support a Cell-Based Enzyme Replacement Therapy in the Gyrate Atrophy of the Choroid and Retina.International journal of molecular sciences · 2024Article
- Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules.Scientific reports · 2024Article
- Drug-loaded erythrocytes: Modern approaches for advanced drug delivery for clinical use.Heliyon · 2024Review
- Compatibility of Nucleobases Containing Pt(II) Complexes with Red Blood Cells for Possible Drug Delivery Applications.Molecules (Basel, Switzerland) · 2023Article
- Evaluation of Two Osmosis-Based Methods for the Preparation of Drug Delivery Systems Based on Red Blood Cells.Pharmaceutics · 2023Article
- Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs.Pharmaceutics · 2023Review
- Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia.Frontiers in oncology · 2023Review
- Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine.Molecular therapy. Methods & clinical development · 2022Article
- Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy.Cancers · 2022Review
- Chemical Conjugation in Drug Delivery Systems.Frontiers in chemistry · 2022Review
- Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance.Pharmaceutics · 2021Review
- Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Engineered red blood cells (RBCs) appear to be a promising method for therapeutic drug and protein delivery. With a number of agents in clinical trials (e.g., dexamethasone 21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer/acute lymphoblastic leukemia, thymidine phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy, RTX-134 in phenylketonuria, etc.), this leading article summarizes the ongoing efforts in developing these agents, focuses on the clinical progress, and provides a brief background into engineered RBCs and the different ways in which they can be exploited for therapeutic/diagnostic purposes. References to available data on safety, efficacy, and tolerability are reported. Due to the continuous progress in this field, the information is updated as of January 2020 from databases, websites, and press releases of the involved companies and information that is in the public domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.